U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.

from Reuters: Health News https://ift.tt/2TaGBfy
via IFTTT